JFS Wealth Advisors LLC Has $1.05 Million Stock Holdings in Pfizer Inc. $PFE

JFS Wealth Advisors LLC trimmed its stake in Pfizer Inc. (NYSE:PFE) by 1.5% in the second quarter, HoldingsChannel reports. The firm owned 43,205 shares of the biopharmaceutical company’s stock after selling 676 shares during the period. JFS Wealth Advisors LLC’s holdings in Pfizer were worth $1,047,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. First Fiduciary Investment Counsel Inc. grew its holdings in Pfizer by 2.1% in the second quarter. First Fiduciary Investment Counsel Inc. now owns 237,043 shares of the biopharmaceutical company’s stock worth $5,746,000 after purchasing an additional 4,928 shares during the period. Strengthening Families & Communities LLC grew its holdings in Pfizer by 871.3% in the second quarter. Strengthening Families & Communities LLC now owns 2,370 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 2,126 shares during the period. Blue Trust Inc. grew its holdings in Pfizer by 3.1% in the second quarter. Blue Trust Inc. now owns 118,351 shares of the biopharmaceutical company’s stock worth $2,869,000 after purchasing an additional 3,548 shares during the period. Fourpath Capital Management LLC grew its holdings in Pfizer by 19.8% in the second quarter. Fourpath Capital Management LLC now owns 36,855 shares of the biopharmaceutical company’s stock worth $893,000 after purchasing an additional 6,095 shares during the period. Finally, Thompson Investment Management Inc. grew its holdings in Pfizer by 1.3% in the second quarter. Thompson Investment Management Inc. now owns 415,996 shares of the biopharmaceutical company’s stock worth $10,084,000 after purchasing an additional 5,151 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 1.7%

PFE opened at $24.81 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company’s 50-day moving average is $24.86 and its 200 day moving average is $24.14. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.82. The firm has a market capitalization of $141.03 billion, a P/E ratio of 13.19, a PEG ratio of 0.83 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the firm earned $0.60 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on PFE shares. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday. Bank of America lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Morgan Stanley reduced their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday. Finally, UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $28.35.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.